Skip to main content
. Author manuscript; available in PMC: 2022 Apr 1.
Published in final edited form as: Small. 2020 Oct 23:e2004258. doi: 10.1002/smll.202004258

Figure 8. Application of our cardiac-breast cancer-on-a-chip platform for further studying cardiotoxicity with NP-based drug delivery system.

Figure 8.

a) Schematic of the procedure to generate GYSM-NP-DOX. b) Representative immunofluorescence images of live/dead staining for iPSC-derived healthy or fibrotic cardiac and BC tissues after 6 days in culture with a supplement of free DOX or NP-conjugated DOX. Cytotoxicity quantification of free DOX, NPs and NP+DOX on c) cardiac and d) BC cells for 5 days in culture using Prestoblue (N=4). EC measurement of e) Troponin T, f) CK-MB, and g) HER-2 rate in the cardiac-breast cancer-on-a-chip with a supplement of free DOX or NP-conjugated DOX (N=3). (One-way ANOVA with Tukey significant difference post-hoc test; *p<0.05, **p<0.005, and ***p<0.0005). Error bars represent standard deviation.